Supreme Court justices on Monday raised tough questions about patents on human genes held by Myriad Genetics Inc.

The nine justices signaled reluctance to issue a broad ruling, indicating that some were looking for a compromise that might distinguish between types of genetic material.

The biotechnology industry warns that a broad ruling against Myriad could threaten billions of dollars of investment.

Forwarding the News

Thoughtful, balanced reporting from the Forward and around the web, bringing you updated news and analysis each day.

Terms(Required)

I agree to the Forward's Terms of Service and Privacy Policy

Email(Required)

A group of medical researchers, associations and patients say human genes, including synthetically produced material, should not be patented. They sued in 2009, challenging seven patents owned by or licensed to Myriad on two human genes linked to breast and ovarian cancer. A federal judge said the patents were invalid. An appeals court overruled that decision, and the case landed at the Supreme Court.

Several justices, including Justice Sonia Sotomayor, signaled on Monday that they did not think that the simple process of isolating and removing human genes should be patented. But others, such as Justice Elena Kagan, indicated concerns about the impact a broad ruling could have on companies that invest in such research.

Justice Samuel Alito appeared most concerned about the court issuing a sweeping ruling on what he described as a “very difficult” question.

“Why should we do that?” he asked.

The Obama administration, which intervened in the case in support of neither side, has urged a compromise position, which several justices probed during the hour-long argument.

Government lawyers say that “synthesized genetic materials” can be patented because they are human-made inventions. But simply removing, or isolating, human DNA does not substantively change it and so it should not be eligible for a patent, the administration says.

If the court were to adopt that approach, which neither the plaintiffs nor Myriad accept, some of Myriad’s patents, concerning synthetic molecules called cDNA, could survive, although the parties disagree on that point as well.

A number of justices indicated concerns about whether Myriad should be awarded patents merely for isolating a gene. A majority appeared inclined to find that cDNA could be patented.

Emphasizing the need to tread carefully, Justice Stephen Breyer noted that patent law often involves “uneasy compromises.”

The U.S. Patent and Trademark Office has granted patents on at least 4,000 human genes to companies, universities and others that have discovered and decoded them.

The Forward is free to read, but it isn’t free to produce

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.

Readers like you make it all possible. We’re near the end of our Passover Fundraising Drive, and we have a very ambitious goal of $127,000 by April 21.

This is a great time to support independent Jewish journalism you rely on. Make a Passover gift today!

—  Rachel Fishman Feddersen, Publisher and CEO

Make a Passover Gift Today!

$90 $180

$360

Other amount